Lynch G R, Gralla R J, Kelsen D P, Casper E S, Stoopler M B, Golbey R B
Cancer Clin Trials. 1981 Fall;4(3):273-6.
A phase II study of metoprine in low dose and in high dose with citrovorum rescue was conducted in patients with non-small-cell lung carcinoma. There were no responses observed in the 36 patients studied, yielding a predicted true response rate of less than 9%. Thrombocytopenia was the dose-limiting toxicity of the low-dose regimen; there was also one episode of leukopenia and sepsis in this group. Although citrovorum rescue obviated hematologic toxicity in the high-dose regimen, mild to moderate neurological toxicity occurred at this dose. Metoprine does not appear to be a useful agent in non-small-cell lung carcinoma when used in the dose schedule employed in this study.
对非小细胞肺癌患者进行了一项关于低剂量和高剂量甲氨蝶呤并采用亚叶酸解救的II期研究。在所研究的36例患者中未观察到反应，预测的真实反应率低于9%。血小板减少是低剂量方案的剂量限制性毒性；该组还发生了1例白细胞减少和脓毒症。尽管亚叶酸解救避免了高剂量方案中的血液学毒性，但在此剂量下出现了轻度至中度神经毒性。在本研究采用的剂量方案中，甲氨蝶呤用于非小细胞肺癌时似乎不是一种有效的药物。
